Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

TORONTO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), today announced it has acquired a pre-clinical platform developing new drugs to treat chronic kidney disease (CKD). The platform includes recently filed patents protecting new compositions and methods targeting a novel mechanism of action involving interleukin-32 (IL-32), which is directly implicated in the progression of CKD.